Tatva Chintan reports strong Q2, H1 FY26 results; appoints new CFO

Tatva Chintan Pharma Chem Limited reported a significant increase in its Q2 FY26 consolidated revenue from operations, reaching ₹1,235 million, a 48% year-over-year rise. Profit after tax (PAT) surged by 1594% to ₹99 million for the quarter, with a PAT margin of 8%. For the half-year ended September 30, 2025, revenue from operations stood at ₹2,404 million, a 27% increase, and PAT reached ₹166 million, up 265% year-over-year.

In a related development, the company announced the appointment of Ajesh Kumar Mohanan Pillai as the chief financial officer (CFO) and key managerial personnel (KMP), effective October 31, 2025. This strategic move aligns with the company's continuous focus on strengthening its leadership team and financial operations.